May 9, 2023

Parvus Therapeutics announces a publication describing the cellular origin of Treg cells generated endogenously by Navacim therapy

Parvus Therapeutics announced today the publication of data showing that peptide-MHC class II-coated nanoparticles (Navacims) operate by triggering the expansion of cognate T follicular helper (TFH) cells. Full Release

November 29, 2021

Parvus Therapeutics Announces Development and Manufacturing Agreement with Resilience to Advance Novel Autoimmune Drug Candidate PVT201

Parvus Therapeutics, a biopharmaceutical company developing Navacim™ platform-based disease-specific immunoregulator therapeutics to treat autoimmune diseases by activating endogenous generation of disease-specific regulatory T cells (Tregs) without impairing normal immune system function, today announced an agreement with National Resilience, Inc. (Resilience), for the tech transfer, scale-up and GMP manufacturing of PVT201, Parvus’ lead Navacim™ drug candidate being developed to treat Primary Biliary Cholangitis. Full Release

November 19, 2021

Parvus Therapeutics and Ardena Enter Agreement for Tech Transfer, Scale-Up and GMP Manufacturing of Navacim Nanoparticles

Parvus Therapeutics is a biopharmaceutical company developing Navacim™ platform based disease-specific immunoregulating therapeutics to treat autoimmune diseases by activating endogenous generation of disease-specific regulatory T cells (Tregs) without impairing normal immune system function. Full Release